BioReference Laboratories Inc. in Elmwood Park acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche. The Harmony Prenatal Test, Ariosa’s non-invasive prenatal screening ...
Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million ...
CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), ...
Transaction to extend Labcorp's (LH) leadership in oncology and expand access to the company's high-quality clinical laboratory services Through this transaction, Labcorp will acquire BioReference ...
ELMWOOD PARK, N.J., April 29, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced that beginning today it will offer antibody blood tests to detect an ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Labcorp continues string of ...
ELMWOOD PARK, N.J., Nov. 28, 2023 /PRNewswire/ -- BioReference ® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a ...
BioReference announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche. Ariosa’s non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results